The cell and gene therapy industry will greatly benefit from access to robust, scalable, end-to-end solutions for the production and characterization of native and engineered exosome therapeutics.” — ...

Optimizing the downstream process for adeno-associated virus (AAV) production with consistent quality depends on the ability to characterize critical quality attributes affecting the final product’s ...

Matt Taylor is a senior process development associate at KBI Biopharma, where he focuses on the design, optimization, and scale-up of purification processes for biopharmaceutical manufacturing. Matt ...